Development of the third generation of FOXO4-based anti-senescence drugs: the FOXO4-DRI peptide. In contract to the earlier versions, this peptide fully contained “D”-amino acids. Moreover, the sequence was inverted. This 3rd generation FOXO4-DRI proved to be effective in counteracting signs of chemotoxicity and, excitingly, was able to restore healthspan in models for fast and natural aging, e.g. fur density, behavior and renal function. (Baar et al., Cell, 2017). This research received worldwide media attention, including coverage in numerous TV and radio shows, newspapers and blogs. Multiple other groups have shown benefits of FOXO4-DRI against (age-related) diseases in mouse models.